《滬深兩市》上證全日微升2點 深成創板反覆升0.4%-0.5% 銀保券商股回軟 醫藥概念股炒上
內地疫情仍然嚴峻,昨日(20日)新增本土確診病例1,947例,新增本土無症狀感染者2,384例。3月LPR維持不變,一及五年期貸款市場報價利率持平於3.7%及4.6%。人民銀行今日(21日)進行300億元人民幣(下同)7天期逆回購操作,單日淨投放200億元。俄烏戰事未完,本週開始新一輪談判,人民幣兌美元中間價今下調252點。上證深成今早高開後反覆靠穩。A股午後一度轉弱倒跌,創板幾乎抹去升幅,至尾市略見承接下回穩微升。
上證全日反覆微升2點或0.08%,收報3,253點;深成指全日升50點或0.4%,收報12,379點;創業板指數升12點或0.5%,收報2,726點,成交2,443億元。上證深成全日成交分別爲4,211億元及5,941億元。
重磅中資金融股偏軟,工行(601398.SH)及建行(601939.SH)分別跌0.2%及0.7%。保險及券商股缺乏支持下回軟,國壽(601628.SH)跌2.5%。華創陽安(600155.SH)及華鑫股份(600621.SH)分別挫6.4%及3.7%。
大地產股普遍回軟,金科股份(000656.SZ)、保利發展(600048.SH)及萬科(000002.SZ)跌1.8%-3.7%。陽光城(000671.SZ)公佈最新兌付方案指將以實物及現金等儘快兌付,股價漲停。
白酒股偏軟,貴州茅臺(600519.SH)及五糧液(000858.SZ)分別跌0.2%及1.3%。
新冠藥物及中藥概念股炒上,益盛藥業(002566.SZ)、衆生藥業(002317.SZ)、康惠藥業(603139.SH)普洛藥業(000739.SZ)及復星醫藥(600196.SH)漲停。華海藥業(600521.SH)及九洲藥業(603456.SH) 分別揚6.4%及7%。
今年二季度電池成本上漲幅度大幅超預期,電動車充電概念股上揚,愛瑪科技(603529.SH)漲停。瀚川智能(688022.SH)揚9.3%。比亞迪(002594.SZ)高開高走升4.6%。寧德時代(300750.SZ)升1.9%。(ta/s) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.